Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MaxCyte Inc MXCT

Technology Scientific & Technical Instruments
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by... see more

Recent & Breaking News (NDAQ:MXCT)

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

GlobeNewswire April 12, 2022

MaxCyte Reports Fourth Quarter and Full Year Financial Results

GlobeNewswire March 22, 2022

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

GlobeNewswire March 9, 2022

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

GlobeNewswire February 24, 2022

MaxCyte to Participate in Upcoming Investor Conferences

GlobeNewswire February 14, 2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 11, 2022

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

GlobeNewswire February 1, 2022

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

GlobeNewswire January 24, 2022

MaxCyte to Participate in Upcoming Investor Conferences

GlobeNewswire November 12, 2021

MaxCyte Reports Third Quarter Financial Results

GlobeNewswire November 10, 2021

MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board

GlobeNewswire November 3, 2021

Result of AGM

GlobeNewswire October 29, 2021

MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

GlobeNewswire October 28, 2021

MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

GlobeNewswire October 25, 2021

MaxCyte Set to Join Russell 2000® Index

GlobeNewswire September 17, 2021

MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections

GlobeNewswire September 13, 2021

MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

GlobeNewswire September 2, 2021

Financial information in the Form S-1 registration statement and Change to Board of Directors

PR Newswire July 12, 2021

MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing

PR Newswire July 12, 2021